Antidiabetics Market Increase in investment towards R&D Driving Sector Growth
The global Antidiabetics Market is estimated to secure US$ 223 Billion while expanding at a CAGR of 9.6% during the forecast period. The growth of the market can be attributed to the increasing prevalence of diabetes across the globe. Also, the aging baby boomer is another factor driving the market in the forecast period.
According to International Diabetes Federation, the global
diabetes incidence is anticipated to increase from 366 million in 2011 to 552
million by 2030. Such a significant increment in the number of diabetic patients
is projected to benefit the industry in the forecast period.
Also, the development of new products is anticipated to
benefit the market in the coming time. For instance, in January 2022, Novo
Nordisk, the Danish drug provider, announced the launch of oral semaglutide in
India for the treatment of Type 2 diabetes. Moreover, the development of
advanced pumps based on smart technologies such as; AI and ML are predicted to
offer various opportunities.
For instance, in July 2021, Ypsomed AG expanded the range
of features of the mylife YpsoPump system. The app-based deployment of the
Dexcom G6 Continuous Glucose Monitoring (CGM) System allows people with
diabetes to manage their therapy through their smartphones.
On the contrary, expenses associated with insulin pumps,
lack of awareness about the treatment methods, and poor reimbursement framework
in developing countries are anticipated to hinder the market growth.
Competition Analysis
Key players in the region include Bayer Corporation,
AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Bristol-Myers Squibb. Recent
key developments in the industry are:
Browse More@ https://www.futuremarketinsights.com/reports/antidiabetics-market
Key Segments Profiled in the Global
Antidiabetics Market Study
Antidiabetics
Market by Product:
- Insulin-based
Antidiabetics
- Rapid-Acting
Analog
- Long-Acting
Analog
- Premixed
Insulin
- Short-Acting
Analog
- Intermediate-Acting
Insulin
- Antidiabetics Drug Class
- Alpha-Glucosidases
Inhibitors
- Biguanides
- Sulphonylureas
- GLP-1
(Glucagon-like peptide) Agonists
- DPP-IV
(Dipeptidyl Peptidase) Inhibitors
- Meglitinides
- SGLT-II
(Sodium-Glucose Transport Proteins) Inhibitors
- Thiazolidinedione
Antidiabetics
Market by Patient Population:
- Antidiabetics
for Pediatrics
- Antidiabetics
for Adults
- Antidiabetics
for Geriatrics
Antidiabetics
Market by Route of Administration:
- Antidiabetics
Administration through Insulin Syringes/ Insulin Pens
- Antidiabetics
Administration through Insulin Pumps
- Intravenous
Antidiabetics Infusion
- Oral
Antidiabetics Administration
- Other
Routes of Antidiabetics Administration

Comments
Post a Comment